CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
CCTG is pleased to announce the agenda for the Plenary Session at the #CCTG2026 Spring Meeting.
Dr. Rebecca Auer is our guest speaker this year at the Maria Ricci Memorial Lectureship In Oncology taking place at the CCTG Spring Meeting
Dear CCTG Members, Volunteers and Supporters,
On behalf of the Canadian Cancer Trials Group to all members and supporters, we extend our sincere gratitude to those who generously contribute their time, experience, expertise, and support to advance cancer research.
CCTG works because so many commit their time energy effort on behalf of our mission and activities—they are a broad and deeply valued community. This includes CCTG patient representatives who share their lived experience, patient participants who make clinical trials possible, clinicians and scientists who contribute their expertise, and research staff across the network who help support and strengthen our work. We also recognize the important contributions of Canadian Cancer Society fundraisers and donors, whose generosity helps sustain research that can improve outcomes for people affected by cancer.
Each contribution matters. Whether through participation in a trial, scientific and clinical leadership, research support, advocacy, fundraising, philanthropy, mentoring, education, or training.Your commitment to sharing knowledge and experience, guiding colleagues, supporting learning, and building capacity within the cancer research community is especially meaningful—strengthening the network today while preparing the next generation of researchers, clinicians, staff, and patient partners for the work ahead. Your involvement helps move cancer research forward and brings hope to patients, families, and communities across Canada.
We are deeply grateful for your dedication, compassion, and commitment. Thank you for being part of this important work and for helping the Canadian Cancer Trials Group continue its mission to improve the lives of people affected by cancer.
With sincere appreciation and deepest gratitude,
Janet Dancey, MD, FRCPC,Chair, Canadian Cancer Trials Group
The results of the BR.31 global Phase III study, testing adjuvant durvalumab in patients with completely resected non–small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology.
Pausing endocrine treatment to attempt pregnancy can be considered - no additional risk of recurrences after 5 years. The MAC18 (POSITIVE) study, evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women
The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) announced the enrollment of the first patient in the third sub study IND240C of their ongoing Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC).
Results from the primary analysis of the ctDNA-negative cohort from the international DYNAMIC-III (CO.29) clinical trial were presented during the Presidential Symposium of the European Society for Medical Oncology Congress in Berlin
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
Combination Therapy with Luspatercept in Lower Risk Myelodysplasia: A Tier 1 myeloMATCH Substudy
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG SR.8 (HARMONY) clinical trial has been awarded almost 1.5 million through the CIHR spring Project Grant Program. A phase III study that addresses a significant unmet need in the treatment of high-risk soft-tissue sarcoma (STS).
We are pleased to welcome Lesley Beaton as the new patient representative supporting the Gastrointestinal Disease Site Committee.
Lesley lives in Vancouver, BC, and brings both scientific and personal experience to her role. She spent more than three decades working in microbiology and regulatory compliance with Health Canada, gaining a scientific perspective on healthcare systems.
Please join us in welcoming Catherine Caule, who is the new patient representative supporting the Hematology Disease Site Committee.
Catherine is a long-time health advocate based in Ottawa, Ontario, and a 25-year member of the Lymphoma Support Group of Ottawa. After being diagnosed with advanced Hodgkin Lymphoma and participating in a clinical trial for relapsed disease, she became a passionate voice for patient-centered care and equitable access.
